SKIN · XBRL financial data

SkinHealth Systems financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (SKIN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	119	260	366	398	334	301
Cost of revenue	52	78	116	243	152	104
Gross profit	67	182	250	155	182	196
Research and development	3	8	8	10	6	6
General and administrative	31	99	106	131	125	118
Total operating expenses	84	218	275	286	250	217
Operating income (loss)	(1)	(37)	(24)	(131)	(68)	(21)
Interest income	—	0	9	23	17	9
Interest expense	—	12	13	14	10	19
Other income (expense)	(0)	(4)	(2)	5	34	19
Income tax expense (benefit)	(9)	(2)	1	(2)	(0)	4
Net income (loss)	(1)	(375)	44	(100)	(29)	(10)
Earnings per share, basic USD per share	(0.85)	(3.67)	0.30	(0.76)	(0.23)	(0.08)
Earnings per share, diluted USD per share	(0.85)	(3.67)	(0.23)	(0.76)	(0.36)	(0.16)
Weighted average shares, basic millions of shares	34	102	148	132	124	126
Weighted average shares, diluted millions of shares	34	102	149	132	142	136

Fiscal years (SKIN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	3	902	568	523	370	233
Marketable securities, non-current	460	—	—	—	—	—
Accounts receivable	19	47	76	55	28	22
Inventory	23	35	116	91	69	48
Prepaid and other current assets	3	12	27	29	9	5
Total current assets	4	1,001	789	698	477	310
Property and equipment, net	9	—	—	—	—	—
Right-of-use asset	0	15	16	12	14	12
Goodwill	99	124	125	126	123	127
Total assets	464	1,219	1,009	929	686	500
Accounts payable	18	29	30	45	22	16
Accrued liabilities	1	15	15	20	20	15
Total current liabilities	1	76	73	115	68	186
Lease liability, non-current	0	13	13	9	11	9
Total liabilities	83	917	837	870	634	439
Accumulated deficit	(39)	(419)	(374)	(479)	(508)	(517)
Total stockholders' equity	5	302	171	59	52	61
Total liabilities and equity	464	1,219	1,009	929	686	500
Common shares outstanding (cover page) millions of shares	36	151	133	123	125	128

Fiscal years (SKIN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(1)	(375)	44	(100)	(29)	(10)
Stock-based compensation	0	12	28	23	27	15
Net cash from operating activities	(12)	(28)	(107)	22	16	37
Purchases of property and equipment	4	11	11	4	1	0
Net cash from investing activities	(4)	(38)	(19)	(32)	(7)	(5)
Share repurchases	0	0	160	30	0	0
Net cash from financing activities	18	959	(205)	(37)	(158)	(175)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
SkinHealth Systems	206	72	2.7*	130.1M	—	Q2 FY26 10-QJun 30, 2026
Sight Sciences	77	25	(2.4)*	55.6M	15.2 quarters	Q3 FY26 10-QSep 30, 2026
Profound Medical	38	2.5	(11)*	36.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Stereotaxis	10	7.7	(3.7)*	100.2M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Utah Medical Products	88	8.5	1.4*	3.2M	—	Q2 FY26 10-QJun 30, 2026
Sanara MedTech	15	28	2*	9.2M	—	Q2 FY26 10-QJun 30, 2026
Anika Therapeutics	38	33	(0.7)*	13.4M	56.2 quarters	Q2 FY26 10-QJun 30, 2026
Heartflow	34	64	(8.6)*	87.0M	19.0 quarters	Q2 FY26 10-QJun 30, 2026
AVITA Medical	9.1	22	(3.5)*	30.9M	3.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.